GILEAD SCIENCES, INC. Debt Instrument, Convertible, Carrying Amount of Equity Component
GILEAD SCIENCES, INC. (GILD) had Debt Instrument, Convertible, Carrying Amount of Equity Component of $733.00 million as of 2016-03-04, per its 10-Q filed 2016-05-06.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent · last filed 2016-05-06
- 2016-03-04: Debt Instrument, Convertible, Carrying Amount of Equity Component $733.00M.
- 2012-12-31: Debt Instrument, Convertible, Carrying Amount of Equity Component $259.54M.
- 2011-12-31: Debt Instrument, Convertible, Carrying Amount of Equity Component $259.54M.
- 2010-12-31: Debt Instrument, Convertible, Carrying Amount of Equity Component $255.52M.
| Period end | Debt Instrument, Convertible, Carrying Amount of Equity Component |
|---|---|
| 2016-03-04 | $733.00M 10-Q · filed 2016-05-06 |
| 2012-12-31 | $259.54M 10-K · filed 2013-02-27 |
| 2011-12-31 | $259.54M 10-K · filed 2013-02-27 |
| 2010-12-31 | $255.52M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |